Erik Rein-Hedin
Erik Rein-Hedin (MD, PhD candidate) is CTC’s deputy Chief Medical Officer (dCMO) and has been with CTC since 2016. Erik has acted as principal investigator and co-investigator in 100+ clinical trials in all clinical phases but is mainly dedicated to Phase I trials in healthy volunteers, including first-in-human.
He has a particular interest in optimizing trial design to ensure safety and scientific value gained, while adopting a subject-centric approach to minimize the burden of participation.
As a CTC-based doctoral student at Uppsala University, he is undertaking a research project which aims to help improve design and conduct of early phase trials in healthy volunteer subjects. Since 2019, Erik is also a board member on the Clinical Trial scientific section of The Swedish Pharmaceutical Society.
Latest publications
Characteristics, Motivations, and Preferences of Healthy Volunteers in Phase I Clinical Trials in Sweden 27 January, 2025
ACD856, a novel positive allosteric modulator of Trk receptors, single ascending doses in healthy subjects: Safety and pharmacokinetics 14 February, 2024
Utilizing venous occlusion plethysmography to assess vascular effects: A study with buloxibutid, an angiotensin II type 2 receptor agonist 1 February, 2024
Impact of Finerenone-Induced Albuminuria Reduction on Chronic Kidney Disease Outcomes in Type 2 Diabetes : A Mediation Analysis 5 December, 2023
Outcomes with Finerenone in Participants with Stage 4 CKD and Type 2 Diabetes: A FIDELITY Subgroup Analysis 7 April, 2023
Cardiovascular Events with Finerenone in Kidney Disease and Type 2 Diabetes 27 August, 2021
Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes 2 December, 2020
Design and Baseline Characteristics of the Finerenone in Reducing Cardiovascular Mortality and Morbidity in Diabetic Kidney Disease Trial 31 October, 2019